HER2 Overexpression as a Predictive Marker in a Randomized Trial Comparing Adjuvant Cyclophosphamide/Methotrexate/5-Fluorouracil with Epirubicin in Patients with Stage I/II Breast Cancer: Long-Term Results
- 1 August 2005
- journal article
- Published by Elsevier in Clinical Breast Cancer
- Vol. 6 (3) , 253-259
- https://doi.org/10.3816/cbc.2005.n.028
Abstract
No abstract availableKeywords
This publication has 35 references indexed in Scilit:
- High-Dose Chemotherapy with Hematopoietic Stem-Cell Rescue for High-Risk Breast CancerNew England Journal of Medicine, 2003
- HER2 Overexpression and Doxorubicin in Adjuvant Chemotherapy for Resectable Breast CancerJournal of Clinical Oncology, 2003
- Clinical significance of HER-2/neu oncogene amplification in primary breast cancer. The South Australian Breast Cancer Study Group.Journal of Clinical Oncology, 1993
- Prognostic significance of HER-2 oncoprotein expression in breast cancer: a 30-year follow-up.Journal of Clinical Oncology, 1992
- Prognostic importance of c-erbB-2 expression in breast cancer. International (Ludwig) Breast Cancer Study Group.Journal of Clinical Oncology, 1992
- Prognostic significance of her‐2/neu expression in breast cancer and its relationship to other prognostic factorsInternational Journal of Cancer, 1991
- Long‐term survival in breast cancer related to overexpression of the c‐erbB‐2 oncoprotein: An immunohistochemical study using monoclonal antibody NCL‐CB11The Journal of Pathology, 1991
- Pathologic findings from the National Surgical Adjuvant Breast and Bowel Project: prognostic significance of erbB-2 protein overexpression in primary breast cancer.Journal of Clinical Oncology, 1990
- Studies of the HER-2/ neu Proto-Oncogene in Human Breast and Ovarian CancerScience, 1989
- Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/ neu OncogeneScience, 1987